John Steadman

John Steadman is an accomplished executive in pharmaceutical sales with over two decades of experience. Currently serving as an Executive Territory Account Specialist at Novartis since November 2018, John successfully launched a first-in-class siRNA medication for atherosclerotic cardiovascular disease and drove consistent growth of Entresto for heart failure in key accounts. Prior to this, John held various roles at Bristol Myers Squibb, including Cardiovascular Executive Specialty Representative, where significant growth of Eliquis was achieved across hospital accounts. John's extensive career also includes leadership positions at Boehringer Ingelheim, where sales and management support for the Southeast Zone were provided, and additional impactful roles in sales management and consulting. John holds a Bachelor of Business Administration from Florida State University, earned in 1991.